Pembrolizumab and Lenvatinib for Platinum- Sensitive Recurrent Ovarian Cancer

This study is testing whether combining two drugs — pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy that cuts off blood supply to tumors) — can help women with recurrent ovarian cancer that previously responded to platinum-based chemotherapy. **You may be eligible if...** - You are female and at least 18 years old - You have been diagnosed with ovarian cancer (epithelial type, excluding low-grade or mucinous subtypes) - Your cancer came back at least 6 months after platinum-based chemotherapy (platinum-sensitive) - You are not pregnant or breastfeeding **You may NOT be eligible if...** - You have low-grade or mucinous ovarian cancer - You are pregnant or breastfeeding - You have significant heart, liver, or autoimmune conditions - You have previously received certain immunotherapy treatments Talk to your doctor to see if this trial is right for you.